Study guide

4.2 Acute Metabolic & Toxicological Emergencies

DHA Healthcare Professional Licensing Assessment - General Practitioner/Doctor Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Chronic Cardiovascular & Endocrine Disorders

1.1 Hypertension Management in Primary Care 1.2 Type 2 Diabetes Mellitus Management 1.3 Dyslipidemia & Thyroid Disorders

2 Chapter 2: Chronic Respiratory, Renal & Musculoskeletal Disorders

2.1 Asthma & COPD Maintenance 2.2 Chronic Kidney Disease 2.3 Chronic Musculoskeletal & Rheumatological Conditions

3 Chapter 3: Acute & Common Medical Problems

3.1 Common Infections in Primary Care 3.2 Anemia & Hematological Disorders 3.3 Acute Neurological Problems 3.4 Common Gastrointestinal Complaints

4 Chapter 4: Emergency Problems & Resuscitation

4.1 Cardiopulmonary Resuscitation & Shock 4.2 Acute Metabolic & Toxicological Emergencies 4.3 Trauma Assessment & Environmental Emergencies

5 Chapter 5: Common Pediatric Problems

5.1 Acute Pediatric Respiratory Infections 5.2 Febrile Seizures & Childhood Dehydration 5.3 Neonatal Jaundice & Pediatric Developmental Milestones

6 Chapter 6: Women's Health & Obstetric Care

6.1 Antenatal Care, Pre-eclampsia & Gestational Diabetes 6.2 Contraception & Menopause 6.3 Common Gynecological Conditions

7 Chapter 7: Common Surgical Problems

7.1 Acute Abdomen 7.2 Hernias, Hemorrhoids & Testicular Torsion 7.3 Abdominal Aortic Aneurysm & Urological Emergencies

8 Chapter 8: Common Psychiatric Problems

8.1 Mood & Anxiety Disorders 8.2 Psychosis, Delirium & Substance Use 8.3 Suicide Risk Assessment & Crisis Intervention

9 Chapter 9: Common Eye & ENT Problems

9.1 Acute Red Eye, Glaucoma & Uveitis 9.2 Otitis Media, Epistaxis & Vertigo 9.3 Common Upper Respiratory ENT Infections

10 Chapter 10: Common Dermatology Problems

10.1 Acne & Psoriasis 10.2 Eczema, Dermatitis & Skin Infections 10.3 Skin Infestations & Cutaneous Malignancies

11 Chapter 11: Family Medicine Concepts & Health Promotion

11.1 Patient-Centered Care & Continuity 11.2 Immunization & Travel Medicine 11.3 Smoking Cessation & Lifestyle Medicine

12 Chapter 12: Screening & Preventive Medicine

12.1 Cancer Screening 12.2 Cardiovascular & Metabolic Risk Screening

13 Chapter 13: Epidemiology, EBM, Ethics & UAE Regulations

13.1 Basic Epidemiology & Outbreak Measures 13.2 Evidence-Based Medicine & Study Designs 13.3 Professionalism, Ethics & UAE Regulations

4.2 Acute Metabolic & Toxicological Emergencies

Key Takeaways Explain This Topic AI

Adult DKA requires diabetes or glucose at least 200 mg/dL, significant ketosis and acidosis; euglycemic DKA is possible. HHS requires severe hyperglycemia, hyperosmolality and absence of significant ketosis/acidosis.

Use adult fluid and insulin pathways with cardiac, renal and osmotic monitoring; dextrose below 250 mg/dL supports continued insulin without hypoglycemia, rather than proving crisis resolution.

If potassium is below 3.5 mmol/L, delay insulin and replace potassium until it exceeds 3.5 mmol/L; adjust ongoing replacement to renal function and a target of 4-5 mmol/L.

Use a timed acetaminophen level and the appropriate nomogram for eligible acute ingestions; start NAC empirically when waiting for testing would delay indicated treatment beyond 8 hours.

In opioid toxicity, support breathing and use naloxone to restore adequate ventilation and airway reflexes; neither full awakening nor a respiratory-rate number alone is the acute treatment endpoint.

Last updated: October 2026

Acute Metabolic & Toxicological Emergencies

Metabolic crises and drug toxicity require immediate assessment of airway, breathing, circulation and the cause of deterioration. The diabetic ketoacidosis (DKA) and hyperosmolar hyperglycemic state (HHS) recommendations below concern adults , based on the 2024 international consensus report . Pediatric DKA requires a pediatric protocol; pregnancy, frailty, heart failure and kidney failure require adapted treatment and specialist input. Treat the precipitant, such as infection, interrupted insulin delivery or myocardial ischemia, alongside the metabolic disturbance.

Distinguish DKA, HHS and overlap

DKA involves severe insulin deficiency and counterregulatory hormone excess. Lipolysis releases fatty acids that are converted to ketones, producing metabolic acidosis. It is common in type 1 diabetes but can also occur in type 2 diabetes. HHS has enough residual insulin to limit substantial ketogenesis, but inadequate control of hyperglycemia: osmotic diuresis produces profound dehydration and hyperosmolality. HHS is more common in older adults with type 2 diabetes. Neither association is an absolute diagnostic rule, and mixed DKA/HHS occurs.

The consensus diagnostic Figure 2 requires all three DKA components or all four HHS components below. Interpret the alternatives within each component carefully.

Component DKA HHS

Diabetes or hyperglycemia Glucose at least 200 mg/dL (11.1 mmol/L) OR a prior history of diabetes, regardless of presenting glucose Plasma glucose at least 600 mg/dL (33.3 mmol/L)

Ketones Blood beta-hydroxybutyrate at least 3.0 mmol/L OR urine ketones 2+ or greater Blood beta-hydroxybutyrate below 3.0 mmol/L OR urine ketones less than 2+

Acid-base state Venous pH below 7.3 and/or bicarbonate below 18 mmol/L pH at least 7.3 AND bicarbonate at least 15 mmol/L

Hyperosmolality Not a required DKA component Effective serum osmolality above 300 mOsm/kg OR total serum osmolality above 320 mOsm/kg

Euglycemic DKA can occur with glucose below 200 mg/dL, including with sodium-glucose cotransporter 2 (SGLT2) inhibitor use, reduced intake or pregnancy. A relatively low glucose does not exclude DKA in a patient with diabetes, significant ketones and acidosis. Direct blood beta-hydroxybutyrate is preferred for diagnosis and monitoring. Urine tests measure acetoacetate rather than the main ketoacid, so they can underestimate early ketosis and remain positive during recovery.

For calculated osmolality, use consistent units: effective osmolality = 2 x sodium + glucose , with sodium and glucose in mmol/L; total osmolality = 2 x sodium + glucose + urea , all in mmol/L, giving an estimated value in mOsm/kg. Do not insert glucose in mg/dL or blood urea nitrogen into that SI-unit formula. For example, sodium 140 mmol/L, glucose 36 mmol/L and urea 10 mmol/L give effective osmolality 316 and total osmolality 326 mOsm/kg . Both exceed their respective HHS thresholds, but the other diagnostic components must also be satisfied.

Mental status ranges from alertness to impaired consciousness; stupor or coma is not required for HHS . An elevated anion gap can support recognition of ketoacidosis when ketone testing is unavailable, but it is not the preferred diagnostic or resolution endpoint. Mixed acid-base disorders and treatment-related hyperchloremic acidosis can mislead interpretation.

Initial assessment and monitoring

Obtain glucose, electrolytes, creatinine, venous blood gas and ketones; assess osmolality in HHS. Record vital signs, mental status, fluid balance and urine output, obtain an ECG, and investigate precipitating illness. Severe DKA, HHS, critical illness or altered consciousness generally requires intensive care. Selected uncomplicated mild or moderate DKA can be managed in a suitably monitored emergency or step-down setting.

During treatment, check capillary glucose every 1-2 hours . Check electrolytes, renal function, beta-hydroxybutyrate and venous pH every 4 hours until DKA resolves; in HHS, check osmolality every 4 hours . Recheck potassium 2 hours after starting insulin and every 4 hours thereafter , with more frequent checks when unstable or receiving intensive replacement. Monitoring and renal assessment are essential parts of treatment, not optional additions to a dosing formula.

1. Restore circulation without an uncontrolled osmotic shift

For adults without cardiac or renal compromise , begin isotonic saline (0.9% sodium chloride) or a balanced crystalloid at 500-1,000 mL/hour for the first 2-4 hours , reassessing perfusion and fluid balance. Subsequent replacement depends on hydration, blood pressure, heart rate, sodium, intake/output and ongoing losses; the consensus aims to correct the estimated deficit over 24-48 hours . Older adults and patients with heart failure or end-stage kidney disease may need smaller boluses, such as 250 mL , with frequent reassessment rather than the standard volume schedule.

In HHS, avoid a glucose decline faster than 90-120 mg/dL/hour , a sodium decline exceeding 10 mmol/L in 24 hours , and aim for an osmolality fall of 3-8 mOsm/kg/hour , avoiding faster correction. Follow serial values and clinical status. Fluid alone can substantially lower glucose, so insulin timing and rate must account for the response to rehydration.

A rise in measured sodium as glucose falls is expected and does not automatically justify 0.45% saline . The consensus reserves hypotonic saline for osmolality that is not falling despite adequate positive fluid balance and appropriate insulin. Do not use a corrected-sodium calculation alone as a fluid-switch algorithm.

When glucose falls below 250 mg/dL , add 5-10% dextrose to the replacement fluid and adjust insulin. This prevents hypoglycemia while allowing ongoing insulin where ketosis or the hyperosmolar crisis has not resolved; it is not a stand-alone guarantee against cerebral edema. In euglycemic DKA , dextrose may be needed alongside isotonic fluid from the start of insulin treatment . Continue controlling the rate of osmotic change and watching for neurological deterioration.

2. Check potassium before insulin

Despite normal or high initial serum potassium, total-body potassium may be depleted. Insulin, correction of acidosis and restoration of renal perfusion can lower the serum concentration rapidly. For potassium, 1 mmol equals 1 mEq , because it is a monovalent ion.

Serum potassium Adult consensus approach, adapted to renal function and monitoring

Below 3.5 mmol/L Delay insulin and begin potassium replacement. The report's potassium text recommends 10 mmol/hour initially; insulin is delayed until potassium rises above 3.5 mmol/L . Reassess promptly.

Below 5.0 mmol/L once insulin can safely proceed Replace potassium to maintain 4-5 mmol/L . For most adults with DKA, the report's text describes 20-30 mmol per liter of IV fluid, adjusted to serial measurements.

At least 5.0 mmol/L Do not automatically add potassium; monitor and begin replacement when it falls below 5.0 mmol/L, accounting for renal clearance.

Confirm renal function and urine output before routine replacement. Use the institution's IV potassium concentration, infusion-pump, access and ECG-monitoring rules; never give IV potassium as a push . Oliguria, dialysis, marked electrolyte disturbance or arrhythmia needs individualized expert management. A concentration in mmol/L is not an infusion rate in mmol/hour: choose the concentration and fluid flow together so the delivered potassium rate stays within the monitored access-specific limit. Do not copy the old blanket 20-30 mEq/hour replacement instruction.

3. Select insulin for the actual crisis

After initial fluid assessment and correction of unsafe hypokalemia:

DKA: A fixed-rate IV short-acting insulin infusion is commonly 0.1 units/kg/hour . An insulin bolus is not an automatic prerequisite; the consensus discusses it when establishing the infusion is delayed. Closely monitored, uncomplicated mild or moderate DKA may use a validated subcutaneous rapid-acting regimen; this is unsuitable for severe/complicated DKA or HHS.

HHS without significant ketosis or acidosis: With beta-hydroxybutyrate below 3.0 mmol/L, pH at least 7.3 and bicarbonate at least 18 mmol/L, use the lower IV rate 0.05 units/kg/hour , coordinated with rehydration and osmolality trends.

Mixed DKA/HHS treatment pathway: Significant ketosis or acidosis in HHS, such as beta-hydroxybutyrate at least 3.0 mmol/L, urine ketones at least 2+, pH below 7.3 or bicarbonate below 18 mmol/L, calls for 0.1 units/kg/hour in the consensus pathway. The HHS diagnostic bicarbonate threshold of 15 mmol/L is therefore not the threshold for choosing the lower insulin rate.

When DKA glucose falls below 250 mg/dL, add dextrose and usually reduce IV insulin to 0.05 units/kg/hour , titrating to about 200 mg/dL while clearing ketoacidosis. In HHS, maintain glucose around 200-250 mg/dL while completing correction. Do not automatically double insulin because glucose has missed an arbitrary hourly fall: reassess fluids, infusion delivery, potassium, ketones and osmolality, then adjust under the monitored protocol. For a 70-kg adult, 0.1 units/kg/hour calculates to 7 units/hour , whereas 0.05 units/kg/hour calculates to 3.5 units/hour ; choosing the correct pathway matters as much as the arithmetic.

Routine bicarbonate is not recommended. The consensus says to consider it for severe acidosis with pH below 7.0 , under expert monitoring; it can worsen hypokalemia. It is not appropriate merely because DKA is present, and the old universal pH-below-6.9 rule should not be used as the current threshold.

4. Confirm resolution and overlap maintenance insulin

DKA resolution requires blood beta-hydroxybutyrate below 0.6 mmol/L AND either venous pH at least 7.3 OR bicarbonate at least 18 mmol/L . Glucose should ideally also be below 200 mg/dL. Do not use anion-gap closure or urine-ketone clearance as the stopping criterion: hyperchloremic acidosis and conversion of beta-hydroxybutyrate to acetoacetate can confuse those tests.

For HHS , the consensus authors propose resolution when serum osmolality is below 300 mOsm/kg , hyperglycemia is corrected with glucose below 250 mg/dL , urine output is above 0.5 mL/kg/hour , and cognition has improved. They acknowledge the absence of a universally agreed HHS resolution definition. A glucose result alone is insufficient.

Plan subcutaneous maintenance insulin using prior treatment, nutritional intake, renal function and hypoglycemia risk. Provide 1-2 hours of overlap between subcutaneous insulin and stopping the IV infusion, ensuring basal coverage; do not stop the infusion simply because glucose has normalized. Address the precipitating cause and a safe ongoing nutrition/insulin plan before discharge.

  • Toxicological Emergencies
  • Paracetamol (Acetaminophen) Toxicity

Pathophysiology: Paracetamol is mainly metabolized by hepatic glucuronidation and sulfation. A smaller fraction forms the reactive metabolite N-acetyl-p-benzoquinone imine (NAPQI), normally detoxified by glutathione. In overdose, glutathione depletion permits NAPQI-related hepatocyte injury and centrilobular necrosis.

Nomogram scope: For a reliably timed, acute ingestion, measure the serum concentration at least 4 hours after ingestion and interpret it against the appropriate treatment nomogram. The 2023 US/Canada consensus uses a treatment line starting at 150 micrograms/mL at 4 hours , with samples interpreted from 4-24 hours . This is the named consensus convention, not a claim that every jurisdiction uses the same line. Unknown timing, repeated supratherapeutic dosing, extended-release preparations and absorption-delaying coingestants need their own toxicology pathway; do not force an unreliable time onto the nomogram.

Do not delay NAC when delay is dangerous: N-acetylcysteine (NAC) replenishes glutathione and reduces injury. Draw the concentration promptly, but when acute toxicity is strongly suspected, start NAC while awaiting the result if waiting would push treatment beyond 8 hours . A patient may initially be asymptomatic with normal transaminases; neither finding excludes a clinically important ingestion. In a stable patient presenting at 6 hours with reliable immediate-release timing, a promptly available level can guide treatment before that window closes.

Treatment and reassessment: Give NAC orally or intravenously using a validated regimen and poison-center/toxicology advice. An initial 21-hour IV course is not an automatic stopping point : reassess acetaminophen concentration, liver injury, coagulation and clinical condition against stopping criteria. Some patients need continued treatment. Activated charcoal is considered according to timing, absorption and airway safety; decontamination must not replace the antidote decision.

Opioid Toxicity

Opioid agonists depress brainstem respiratory drive. Slow or shallow breathing, reduced consciousness and miosis suggest opioid toxicity, but pupils alone neither establish nor exclude it. Assess other causes and coingestants while supporting the patient.

Immediate support: Open the airway and assist ventilation with oxygen and bag-mask support when needed. A patient with a definite pulse and inadequate breathing needs ventilatory support; if cardiac arrest is suspected, provide standard CPR with breaths and do not delay it for naloxone. These priorities follow the 2025 AHA special-circumstances guideline .

Naloxone endpoint: Give naloxone to reverse opioid-induced respiratory depression. In monitored IV treatment, titrate according to the clinical response and protocol toward adequate spontaneous ventilation and protective airway reflexes , rather than full alertness or a particular pupil size. Assess breathing depth, rate, gas exchange and airway protection together; a rate above 12/minute alone does not prove adequate ventilation. Severe apnea or hypoxemia requires prompt effective reversal and ventilation, not slow titration that delays resuscitation.

Withdrawal and recurrence: Reversal can precipitate withdrawal, including agitation and vomiting, but fear of withdrawal must not delay life-saving respiratory support. Naloxone may wear off before a long-acting or sustained-release opioid. Continue observation for recurrent depression; repeated doses or an infusion may be needed. The acute antidote endpoint is not a discharge criterion: observation should establish low recurrence risk, normal consciousness and normal vital signs before discharge is considered.